AQEMIA, a tech-enabled drug discovery company, has raised an additional €30 million in Series A funding, bringing the total to €60 million. The funding round was led by Wendel Growth and included contributions from Bpifrance Large Venture, Eurazeo, and Elaia. AQEMIA uses generative AI and deep physics for drug discovery and has recently signed a $140 million drug discovery deal with Sanofi. The new funding will accelerate the growth of AQEMIA’s drug discovery projects and further develop its proprietary GenAI and deep physics drug discovery platform.
AQEMIA Secures Additional Funding for Drug Discovery Efforts
AQEMIA, a company specializing in drug discovery through generative AI and deep physics, has raised an additional €30 million in investment. This follows a previous funding round last year, bringing Series A funding to €60 million. The investment was led by Wendel Growth and included contributions from Bpifrance Large Venture, Eurazeo, and Elaia, who are long-standing AQEMIA partners.
The funding comes on the heels of AQEMIA’s recent successes in drug discovery, including a $140 million deal with Sanofi. The additional funds will be used to expand AQEMIA’s proprietary pipeline of drug discovery projects and further develop its GenAI and deep physics drug discovery platform. The company’s internal pipeline already includes several projects being tested in animals, primarily in oncology and immuno-oncology.
AQEMIA’s Mission and Future Plans
As AQEMIA grows, it aims to reshape the drug discovery landscape. The company plans to expand its team with top-tier talents and push technological boundaries. AQEMIA is committed to leading the change in a new era of drug discovery innovation.
Maximilien Levesque, CEO and co-founder of AQEMIA, stated that the company is set to accelerate its drug discovery programs, build a larger proprietary pipeline beyond its projects already tested in animals, and shape a global organization that embraces generative AI and rigorous physics as key instruments to bring excellence in small molecule drug discovery.
About AQEMIA
AQEMIA is a next-generation pharmatech company that aims to design fast, innovative drug candidates for dozens of critical diseases. The company’s unique approach uses quantum and statistical mechanics algorithms to fuel a generative artificial intelligence that designs novel drug candidates. AQEMIA has already achieved several drug discovery successes in its internal pipeline and collaboration with pharmaceutical companies.
About the Investors
Wendel Growth, the lead investor in this funding round, invests in innovative, high-growth companies. It has already committed over €200 million in recent years and is looking for direct investment and co-investment opportunities in start-ups. Other investors include Bpifrance Large Venture, a €1.75 billion fund dedicated to fast-growing, highly innovative startups; Eurazeo, a leading European investment group with €33.5 billion in diversified assets under management; and Elaia, a European top-tier VC firm with a strong tech DNA.
The Future of Drug Discovery
The funding secured by AQEMIA signifies a growing interest in the use of AI and deep physics in drug discovery. As AQEMIA continues to develop its proprietary pipeline and platform, it is likely that we will see more advancements in this field. The company’s commitment to reshaping the drug discovery landscape could potentially lead to faster and more effective treatments for a variety of diseases.